Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-102"

PredicateValue (sorted: default)
dcterms:Is Part Of
lpv:document identification number
lpv:spoken text
"Mr President, as the Commissioner has said, it is an exciting time in medical research. We are on the verge of new breakthroughs, and the root for these is the development of advanced therapies, using gene and cell therapies and tissue engineering. Gene therapy and somatic cell therapy products are already being clinically tested. Some of the tissue engineering products are already with us. This proposal is there to ensure that we deal with a complex issue in a sensible and universal way, through central authorisation so that we can pool scarce expertise at Community level, ensure the highest standards of patient safety across the EU and enable access to the European market and thus to all patients. That is what it is all about and on that basis, I welcome my honourable friend’s report and congratulate him on the work that he did, not only in bringing the report through our Committee on the Environment, Public Health and Food Safety but in the subsequent work he has done negotiating with the Presidency in the trialogue. We needed to look at various issues: the hospital issue, the small and medium enterprise issue, the medical devices issue. Of course, with this comes a number of ethical issues and those are important. However, my belief is that the EU’s job is to guarantee safety and efficacy, and Member States should take the ethical decisions. I believe that is where we will conclude on this important measure. We now have to look very carefully at the options before us in the votes on Wednesday to make sure that we take something through which has the wholehearted support of this House."@en1

Named graphs describing this resource:


The resource appears as object in 2 triples

Context graph